Citi analyst Yigal Nochomovitz raised the firm’s price target on Zymeworks (ZYME) to $19 from $18 and keeps a Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks: Promising Pipeline and Financial Stability Justify Buy Rating
- Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes
- Zymeworks’ Earnings Call: Achievements and Challenges
- Zymeworks: Hold Rating Amid Limited Near-Term Catalysts and Strategic Resource Allocation
- Zymeworks Reports 2024 Financial Results and Pipeline Progress
Questions or Comments about the article? Write to editor@tipranks.com